Form 4: ArriVent BioPharma Director Kristine Peterson Acquires Stock Options

Kristine Peterson, a director at ArriVent BioPharma, acquired stock options exercisable for 28,587 shares of common stock on April 22, 2024.

Summary

• On April 22, 2024, Kristine Peterson, a director of ArriVent BioPharma, Inc., was granted stock options.
• The stock options allow her to purchase 28,587 shares of common stock at an exercise price of $15.90 per share.
• The options vest on the first anniversary of the grant date, contingent upon her continued service.
• Following the transaction, Peterson directly owns 28,587 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants. It indicates confidence from the director but doesn't provide specific financial insights.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options is contingent upon continued service, implying an expectation of ongoing involvement.

Industry Context

This is a routine disclosure of stock option grants to a company director, a common practice in publicly traded companies to align management's interests with those of shareholders.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates